No Data
No Data
Kepei-B plans to repurchase company shares for no more than 50 million yuan.
Kepei-B (02487) announces that the company plans to implement a stock repurchase plan from July 15, 2024 to December 31, 2024 (including the first and last day). The stock repurchase plan will be implemented by exercising the power under the general authorization granted by the shareholders to the board of directors at the annual general meeting to be held on June 5, 2024. The company plans to repurchase its shares in the open market according to the following parameters: 1. The upper limit of the funds used to repurchase shares: RMB 50 million. 2. Period of the stock repurchase plan: from July 15, 2024 to 2
Kadepa-B (02487.HK): implementation of the share repurchase plan based on the share repurchase authorization.
On July 12th, Gelunhui announced that Kodibe-B (02487.HK) plans to implement a share repurchase plan from July 15, 2024 to December 31, 2024 (including the first and last day). The share repurchase plan will be implemented by exercising the power under the general authorization for repurchasing shares granted by the shareholders at the annual general meeting of the board of directors held on June 5, 2024. The maximum amount of funds for repurchasing shares is RMB 50 million (equivalent to about HKD 54.7 million). For illustration purposes only, assuming RMB 50 million is obtained.
Express News | Cutia Therapeutics - Intends to Implement Share Repurchase Program From 15 July to 31 Dec
Cutia Therapeutics Enrolls Final Patient in Phase II Trial of Weight Loss Drug
Cutia Therapeutics (HKG:2487) enrolled the last patient for its Phase II clinical trial of weight loss drug CU-20401, according to a June 28 filing on the Hong Kong bourse. CU-20401 targets obesity, o
Cutia Therapeutics Likely Shifting to Focus on Healthcare Consumer Products -- Market Talk
0456 GMT - Cutia Therapeutics is likely gearing toward consumer healthcare products rather than solely biotech innovations, Deutsche Bank analysts say in a note; it raises its 2024 and 2025 revenue fo
Cotech-B (02487.HK): The phase II clinical trial of CU-20401 (recombinant mutant collagenase) for the treatment of submental fat accumulation has completed the enrollment of the last subject.
On June 28, Gelonhui announced that Kedi-B (02487.HK) has completed the last subject entry for Phase II clinical trial of CU-20401 (recombinant mutant collagenase), a potential class 1 new drug for treating submental fat accumulation. CU-20401 is a recombinant mutant collagenase that targets metabolic diseases related to obesity, overweight, or other local fat accumulation. CU-20401 uses an innovative mechanism of action, as a collagenase, it selectively acts on the extracellular matrix attached to adipose tissue. After local injection, CU-20401 degrades subcutaneous tissue.
No Data